Bispecific antibodies can recognize two different antigens, offering new possibilities for therapeutic development. However, understanding how binding to one target influences interactions with another can be challenging. Characterizing these binding events is important for evaluating antibody function and guiding molecular design.
This application note examines how biolayer interferometry (BLI)-based dual binding assays can characterize interactions between the bispecific antibody zenocutuzumab and its targets, HER2 and HER3, including the effects of sequential antigen binding.
Download this application note to learn:
- How dual binding assays characterize interactions between bispecific antibodies and two distinct antigens
- How antigen binding order can influence subsequent interactions with a second target
- How BLI can help investigate binding behavior and assess the functional properties of bispecific antibodies
